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ABSTRACT 
Objective: This study aims to determine the effect of fortified dadih with vitamin D3 on IL-6 expression level and the concentration of caecum SCFA 
in obese rats. 
Methods: A total of 30 male Sprague Dawley rats were divided into five equal groups: healthy-control-(K-), obese-control-(K+), obese-intervention-
(X1, X2, and X3). K(+), X1, X2, and X3 were in obesity conditions, which was induced by a high-fat sucrose diet (HFSD) and K(-) as a healthy-control-
group. Furthermore, vitamin D3-fortified dadih at doses of 4 g/200 g-body-weight/d, dadih only at doses of 4 g/200 g-body-weight/d, and vitamin 
D3 only at 36 IU/200 g-body-weight/d was administered to X1, X2, and X3 groups, respectively.  
Results: Treatment using fortified dadih with vitamin D3 showed significantly reduce weight gain (p<0.05) compare to K(+) and X2. In addition, X1 
showed a decreased level of Interleukin-6 expression (p<0.05) than K(+), X2, and X3 groups but higher than K(-). Also, it showed the highest total 
SCFA, acetate, and propionate concentration (p<0.05). However, a moderately negative correlation was discovered between the pair of total SCFA 
and Interleukin-6 expression, acetate and Interleukin-6 expression, SCFA and body weight, propionate and body weight, butyrate and body weight. 
On the contrary, a strong positive correlation was observed between the pair of Interleukin-6 expression levels and body weight. 
Conclusion: This study shows that fortified dadih with vitamin D3 from fermented foods improve the expression level of Interleukin-6 and increase 
the production of SCFA. Also, they improve intestinal homeostasis because of the increased SCFA production. 
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INTRODUCTION 
Obesity is a chronic metabolic disorder characterized by increased fat 
storage in the body [1, 2]. When energy consumption exceeds 
expenditure, 60-80% of the excess is stored as body fat [3]. Its 
development is not only a balance between energy intake and 
expenditure but also between white and brown adipose tissue in the 
form of thermogenesis through increased expression of mitochondria 
Uncoupling Protein 1 (UCP-1) [4]. At the developmental stage, 
enlargement of adipose tissue caused adipocyte hypertrophy [5], and 
this increased production of Tumour Necrotic Factor-Alpha (TNF-a), 
Interleukin-6 (IL-6) and Monocyte Chemotactic Protein-1 (MCP-1) [6]. 
Dadih is a traditional food from West Sumatera, Indonesia, and it is 
also known as fermented buffalo milk [7]. Some of the LAB that is 
usually found in dadih are Lactobacillus Plantarum, Leuconostoc 
Mesenteroides, Streptococcus Faecalis, S. lactis subspecies lactis, S. 
cremoris, L. casei subspecies casei, and Lactobacillus casei subspecies, 
Rhamnosus, and Lactococcus [7]. In addition, as a regulator of 
obesity, LAB helps to reduce fat absorptions, energy intake, the 
weight of white fat tissue, the average size of adipocytes, modulates 
intestinal microbiota, as well as inhibits the differentiation of 3TL-LI 
adipocytes, and the growth of pathogenic bacteria in the 
gastrointestinal tract [8–12]. Pathogenic bacteria within the gut 
stimulate production and secretion of Lipopolysaccharides (LPS) 
from intestinal epithelial cells, and they bind to cytokine receptors 
on hepatocytes and adipocytes to trigger the release of pro-
inflammatory cytokines (TNFa, IL6, IL1b, and MCP1). However, 
probiotic therapy with LAB reduced the release of LPS from the 
intestinal epithelial cells, and it decreases the production of 
proinflammatory cytokines in adipose tissue [13]. 
Modulated intestinal microbiota with probiotics is a promising 
approach to improving host health since it is protected from infection 
and disease as well as produces vitamins and Short Chain Fatty Acids 
(SCFAs) [14, 15]. In the intestinal lining, it contributes to energy 
metabolism through the production of SCFAs, which are usually 
produced from the fermentation of fibers, proteins, and peptides [16]. 
The end products of this reaction are acetate, propionate, and 
butyrate. Cell culture studies showed that these products can change 
the function of adipose tissue by reducing the production of 
proinflammatory molecules and stimulating adipogenesis. In addition, 
oral administration of butyrate influences weight control through 
increased energy expenditure and fat oxidation in obese rats [17]. 
Vitamin D is an important regulator of immunity, composition and 
function of intestinal microbial, and metabolic processes in the body 
[18–20]. The deficiency of vitamin D leads to several diseases such 
as obesity, diabetes, cardiovascular disease, and metabolic 
syndrome [21]. Research showed a relationship between its 
deficiency and obesity since obese individuals tend to have a low 25 
hydroxyvitamin D (25(OH)D) serum level [22–24]. Furthermore, the 
fortification of dadih with vitamin D3 is expected to increase its 
intake in obese people. The active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) inhibits IL-6 secretion by 
suppressing phosphorylation of Akt and signaling of Nuclear Factor 
Kappa Β (NF-kB) [25]. Yogurt is a fermented milk product similar to 
dadih, and when fortified with vitamin D, it caused weight loss in 
obese patients with type 2 diabetes mellitus [26]. 
This study aimed to determine the effect of fortified dadih with 
vitamin D3 on IL-6 expression level and concentration of caecum 
SCFA in obese rats. 
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MATERIALS AND METHODS 
Dadih preparation 
100 ml buffalo milk was pasteurized at 72 °C for 15 s [27] and cooled 
until 30 °C, then vitamin D3 was added at a dose of 900 IU. 
Pasteurized milk was poured into a clean bamboo tube and then 
covered with banana leaves (fig. 1). The tube was placed at room 
temperature for two days. The dadih is stored at-18 °C (frozen) for 
future uses (fig. 2). 
 
 
Fig. 1: Fortified dadih during spontaneous fermentation 
 
 
Fig. 2: Fortified dadih after fermentation 
 
Research design and experimental-animals 
This research was a true-experiment study using a randomized post-
test with control group design only. The animal used was male 
Sprague Dawley rats, aged 8–12 w, weighing 150–200 g. They were 
acclimatized at the laboratory of the Center for Food and Nutrition 
Studies at Gajah Mada University, Yogyakarta. In addition, they were 
placed in individual stainless-steel cages at regulated temperatures 
(21 °C) and housed in a cleaned and germ-free place. The 
experimental animals were fed with 20 g/d of the Comfeed II 
standard-diet (7% fat) during the non-HFSD and intervention 
period. Also, they received ad-libitum water during the experiment, 
and animal care was performed following the Guidelines of the 
Central Laboratory for Food and Nutrition Studies. 
Thirty rats were divided into five groups, which were obese-control-
(K+), obese-intervention-(X1, X2, and X3) and healthy-control-(K-)-
groups. The obese-condition was induced by HFSD for 28 d, and 
after this period, the X1, X2, and X3-groups were treated daily with 
vitamin D3-fortified dadih at doses of 4 g/200 g-body-weight/d, 
dadih without fortification at doses of 4 g/200 g-body-weight/d, and 
vitamin D3 at doses of 36 IU/200 g-body-weight/d, respectively. The 
blood sample and caecum digesta were obtained at the end of the 
intervention. Furthermore, IL-6 level and SCFA concentration were 
analysed by ELISA (EliKine™, China) and gas chromatography, 
respectively. This study was approved by the Health Research Ethics 
Commission (KEPK) of the Faculty of Medicine Diponegoro 
University, Semarang through ethical clearance No. 
129/EC/H/KEPK/FK-UNDIP/X/2019. 
Serum IL-6 determination 
The determination of serum IL-6 was performed using ELISA-Kit 
according to the manufacturer's instructions (EliKine™, China). Also, 
100 µl of standard and serum of each sample were transferred into 
well plates, which were sealed with a cover and incubated at room 
temperature for 2 h. After incubation, the wells were aspirated and 
washed by filling them with washing buffer (250 µl), repeating the 
process twice for a total of three washes. 100 µl of diluted Mouse IL-
6 detected antibodies within the well and incubated at room 
temperature for 1 h. Thereafter, the wells were aspirated and 
washed by filling them with washing buffer (250 µl), repeating the 
process twice for a total of three washes. Similarly, 100 µl of the 
working dilution of Streptavidin-HRP was added to each well. In 
addition, the plate was sealed with a cover and incubated at room 
temperature for 30 min in the dark, and the wells were aspirated 
and washed by filling them with washing buffer (250 µl), repeating 
the process twice for the total of three washes. 100 µl of HRP 
substrate (TMB) was also added and sealed with a cover. 
Furthermore, it was incubated at room temperature for 15 min in 
the dark. Finally, 50 µl of stop solution was added, and the color 
turned yellow immediately. The sample's absorbance was further 
read by ELISA Reader at 450 nm. 
SCFA determination 
The SCFA determination was performed using gas chromatography, 
and a total of 0.05 g of caecal content was acidified with 0.05 ml of 
sulphuric acid. Furthermore, SCFA was extracted with 0.6 ml of 
diethyl ether and centrifuged at 14000 r. p. m. for 30 s. One 
microliter of the organic phase was injected directly into the 
capillary column (Nukol) of the gas chromatography, which was 
combined with a flame ionization detector. The initial temperature 
was 80 °C while the final was 200 °C. Nitrogen was used as a carrier 
gas and sample quantification was performed using a calibration 
curve for acetic, propionic, and butyric acid. A standard curve was 
performed for the quantitation of acetic, propionic, and butyric acid 
in the sample [28]. The total SCFA is the amount of acetate, 
propionate, and butyrate [29]. 
Chemicals and reagents 
Sulphuric acid and diethyl ether were purchased from Sigma-Aldrich 
Co, St Louis, MO, USA. Vitamin D3 and ELISA Kit were purchased 
from Wellness Inc., USA, and Abbkine Inc., Wuhan, Hubei, China, 
respectively. 
Statistical analysis 
The results were expressed as mean±SD (for normally distributed 
data), which was otherwise manifested as a median (min-max). The 
statistical, the difference was analyzed using One-Way Analysis of 
Variance (ANOVA) followed by post hoc Bonferroni for normally 
distributed data. In addition, the Kruskal Wallis test followed by 
Mann-Whitney-U-test was used (SPSS 16). Spearman's correlative 
test was used to analyze the correlation between variables, and 
statistical analyses were performed by a computer. Likewise, the 
differences and correlations were considered significant at p-
value<0.05 as well as 95% confidence intervals, and its strength was 
determined by r value. 
RESULTS AND DISCUSSION 
Body weight 
The processed data were obtained from 30 Sprague Dawley-rats, 
which were divided into each group consisting of 6. There was an 
increase in body weight during the HFSD period in groups K (+), X1, 
X2, and X3 (they had p = 0.001; table 1). Furthermore, the body 
weight in K (-) increased even though it only received a standard 
feed. The weight gain of those that received HFSD was higher than K 
(-) that received a standard feed. However, bodyweight increase 
during the HFSD period was caused by a higher proportion of fat and 
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sucrose. Therefore, K (+), X1, X2, and X3 groups have higher weight 
gain than K (-). The consumption of high-energy foods such as fat 
and sugar are the main factors that cause obesity [30]. Also, previous 
studies have suggested that HFSD increased body weight to 51% fat 
and 24% lean mass due to changes in composition [30]. 
After intervention of fortified dadih, dadih without fortification, and 
vitamin D3, K (+) gained more body weight compared to K (-), X1, 
X2, and X3 groups. A statistical difference was obtained on the pre-
post-intervention change (Δ) of rat-BW across the groups (Kruskal 
Wallis test; p = 0.001) followed by a Mann Whitney U-test between 
two-groups. However, there was no significant difference between 
X1 and X3 groups compared with K (-) (p=0.545, p=0.789, table 1). 
In addition, it was reported that fortified dadih with vitamin D3 
reduced body weight gain in obese rats since it contained LAB. 
Several studies have shown that LAB and vitamin D3 can reduce gain 
in body weight and epididymal fat mass [8, 31]. Similarly, research 
on the administration of Lactobacillus Plantarum Strain Ln4 reduced 
weight gain in mice [32]. Vitamin D has been reported to have a link 
with obesity as some studies showed that its concentration is low in 
obese individuals [33, 34]. Furthermore, its deficiency causes a 
decreased amount of intestinal calcium and phosphorus absorption, 
which increases PTH levels [35]. This increase has been 
hypothesized as an independent predictor of obesity. One 
hypothesis suggested that high physiological levels of PTH will 
increase calcium influx to adipocytes. In addition, it leads to 
increased lipogenesis and reduced catecholamine-induced lipolysis 
as a mechanism to increase fat storage [36]. 
IL-6 expression level 
The post-intervention-IL-6-levels was significantly different 
between the groups (p=0.000; table 1). Its levels of X1 was 
significantly different with K (+), X2 and X3 groups (p=0.000, 
p=0.000, and p=0.003, respectively; table 1), while the mean values 
were lower compared to X2 and X3. This result showed that fortified 
dadih with vitamin D3 reduced the production of proinflammatory 
cytokines compared to those without fortification and vitamin D3. 
Obesity, which causes inflammation, is characterized by increased 
circulation of inflammatory cytokines and adipokines [37]. Various 
pro-inflammatory and anti-inflammatory factors such as adipokines, 
leptin, adiponectin, resistin, as well as cytokines and chemokines, 
such as TNF-α, IL-6, and MCP-1 are produced and released by 
adipocytes [38]. 
Lactic Acid (LA) as the main metabolite of LAB reduces the production 
of inflammatory cytokines. Furthermore, it decreases pro-
inflammatory cytokines especially TNF-α and IL-6 by reducing 
phosphorylation of IκBα since it inhibits the activation of NF-κB [39]. 
As shown in several studies, some LABs similar to dadih may reduce 
the production of pro-inflammatory cytokines. Research on the 
administration of L. curvatus HY7601 and L. Plantarum KY1032, 
which was obtained from the Korean traditional fermentation of 
cabbage reduced the expression of IL-6 gene in rat epididymal fat 
[13]. Administration of Lactobacillus casei strain Shirota 
supplements to the experimental animals also reduced its 
production [40]. 
An active metabolite of vitamin D, 1,25(OH)2D inhibits 
proinflammatory cytokine production (IL-1β, IL-6, IL-8, IL-12), 
reduces inflammatory activity in adipocytes and inflammation in 
visceral fat tissue [34]. In addition, it suppresses the ability of T cell 
and monocyte proliferation as well as its stimulation and 
decreases proinflammatory cytokines such as C Reactive Protein 
(CRP), TNFα, IL 6, IL-1, and IL-8, and increases anti-inflammatory 
types such as IL-10. This metabolite a ligand for the vitamin D 
receptor (VDR) [41], which inhibits NFkB activation and signaling 
[42]. In vitro study also showed a link between the absence of VDR 
and increased activity of NF-kB [43]. However, inflammatory 
signaling was mediated by the NFkB pathway since it increased 
the expression of proinflammatory cytokines such as IL-6 and 
TNF-α [44]. 
SCFA concentration and ratio 
The post-intervention total of SCFA, acetate, and butyrate 
concentration was significantly different between groups (p=0.029, 
p=0.013, and p=0.022, respectively; table 1). Their concentrations of 
X1 were significantly different with K (+) (p=0.016; p=0.016; and 
p=0.016; table 1, respectively) but not with K (-) group (p=0.109; 
p=0.150; and p=0.262; table 1, respectively). Similarly, their 
concentrations were significantly different from the X3 group but not 
with X2. The mean of total SCFA, acetate, and propionate 
concentration of X1 was higher compared to other groups. This result 
showed that fortified dadih with vitamin D3 is better at producing 
SCFA compared to those without fortification and vitamin D3. 
Furthermore, the ratio of acetate, propionate, and butyrate was 
significantly different between groups (p=0.001, p=0.001, and 
p=0.001, respectively; table 1). There are several references to this 
ratio, such as 60:20:20 and 60:25:15 [45, 46]. The difference 
depends on the type of substrate, diet, and composition of the 
intestinal microbiota [46, 47]. 
The production of SCFA by microbial fermentation of dietary fiber 
was associated with various health benefits, including 
improvements in body composition, energy homeostasis, lipid 
profile, and weight loss by stimulating several hormonal and nerve 
pathways, such as appetite control, increased oxidation, and muscle 
thermogenesis as well as liver tissue [17]. Its effect on body weight 
and food intake occurs through G-protein coupled receptors (GPR, 
GPR41, and GPR 43). GPR41 and GPR 43 are known as a Free Fatty 
Acid Receptor 3 (FFAR3) and 2 (FFAR2), respectively. FFAR2 is 
expressed on immune cells and primarily reacts to acetate and 
propionate, while FFAR3 is mostly present in adipocytes and 
preferentially binds to propionate and butyrate. Their activation 
increases the synthesis and signaling of satiety hormones such as 
GLP-1 and PYY, causing decreased appetite and increased energy 
expenditure [48]. 
The correlation between variables 
The Spearman test showed that a moderate correlation was 
obtained between variables. A moderate negative correlation was 
observed between total SCFA and IL-6-levels (p=0.021; r=-0.419; 
table 2). Furthermore, it was observed between acetate and IL-6-
levels (p=0.027; r=-0.403; table 2) as well as between body weight 
and each of total SCFA, propionate, butyrate (p=0.020; r=-0.423, 
p=0.037; r=-0.383, p=0.008; r=-0.473, respectively; table 2). Also, a 
very strong positive correlation was observed between body weight 
and IL-6-levels (p=0.000; r=0.802; table 2). 
SCFA prevented the production of LPS from gram-negative bacterial 
cell membranes, and it has been linked to endotoxemic metabolism, 
inflammation, insulin resistance, adiposity, and liver fat [49]. 
Furthermore, SCFA reduces systemic inflammation through 
molecular signaling pathways by activating G-protein coupled 
receptor 41/43 and inhibition of the histone deacetylase (HADACs) 
[50, 51]. 
The effect of SCFA on body weight and food intake occurs through G-
protein coupled receptors (FFAR3 and FFAR2). Their activation 
increases the synthesis and signaling of satiety hormones such as 
GLP-1 and PYY, causing decreased appetite and increased energy 
expenditure [48]. Butyrate prevents obesity by activating β3 
adrenergic receptors in white adipose tissue. Acetate plays a role in 
regulating appetite in the brain, increasing fat oxidation, improving 
glucose homeostasis, and inflammatory status [52]. However, its role 
in the regulation of appetite, fat, and weight gain remains 
controversial. Besides, a previously conducted study has reported its 
influence on central appetite regulation and reduced food intake 
[53]. Other studies showed the opposite effect, causing an increase 
in ghrelin secretion, hyperphagia, and obesity in rats [54]. These 
conflicting results may be related to metabolic status and the 
location of its administration [52]. Similar to these results, acetate 
does not have a significant correlation with body weight. In humans 
and mice, propionate is associated with preventing the accumulation 
of hepatic lipids through the suppression of genes involved in fatty 
acid synthesis [52].
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Table 1: The effect of fortified dadih with vitamin D3 on body weight, IL-6 and SCFA 
Groups 
Marker 
K(-) K(+) X1 X2 X3 p1 



























































































































































































































































Five groups of rats (n=6 for each group) consists of K(-): control healthy and K(+): control Obese; X1: Fortified Dadih Treatment; X2: Dadih 
Treatment; X3: Vitamin D3 Treatment; ∆: changes between pre and post value; differences between the groups of rats were analyzed using ANOVA 
(BW HFD, IL-6, Ratio of Acetate, Propionate, and Butyrate) Kruskal Wallis (BW intervention, Total SCFA, acetate, propionate, butyrate); p: value 
between pre and post-treatment were analyzed using Paired t-test/Wilcoxon test; alphabetical superscripts showed a significance level of a: p<0.05 
compared as K(-); b: p<0.05 as compared to K(+); c: p<0.05 as compared to X1; d p<0.05 as compared to X2; e p<0.05 as compared to X3. The data 
were written as mean±SD for normally distributed data and median (Min-Max) when data were not normally distributed; p1: value between all of 
the groups were analyzed using ANOVA if data are normally distributed and Kruskal Wallis if data are not normally distributed. 
 
Table 2: Correlation between SCFA concentration, IL-6 levels, and body weight after fortified dadih with vitamin D3 intervention 
 IL-6 Body weight 
r p r p 
Total SCFA -0.419 0.021* -0.423 0.020* 
Acetate -0.403 0.027* -0.359 0.052 
Propionate -0.355 0.054 -0.383 0.037* 
Butyrate -0.286 0.126 -0.473 0.008* 
Body Weight 0,802 0.000* - - 
Thirty-five of rats were analysed, statistical significance calculated by Spearman test *Value are statistically significant at p<0,05  
 
The expansion of adipose tissue in obesity caused high IL-6 in blood 
circulation [55]. The expression of white adipose tissue and plasma 
IL-6 correlate with increased body mass, waist circumference, and 
free fatty acid levels [56]. In addition, increased expression of IL-6 
Receptor (IL-6R) and IL-6 in adipose tissue was positively correlated 
with clinical indicators of obesity, such as body mass index and fat 
percentage [55]. 
Considering the results, it is reasonable to conclude that fortified dadih 
with vitamin D3 significantly reduces IL-6 expression level and increases 
the production of SCFA. However, the IL-6 expression level was not 
significantly different from healthy-control since it was lower than 
obese-control, dadih without fortification, and vitamin D3 groups. 
Furthermore, the total SCFA, acetate, and propionate concentration of 
fortified dadih with vitamin D3 groups were higher compared to others. 
CONCLUSION  
Fortified dadih with vitamin D3 reduces weight gain, improves the 
expression level of IL-6, and increases the production of SCFA. Also, 
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they improve intestinal homeostasis because of the increased SCFA 
production. The strong correlation between IL-6 and body weight 
indicated that the improvement of IL-6 related to the reduction of 
body weight gain.  
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